

DISCLAIMER

This presentation contains forward-looking statements that reflect the current views of management, and which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. Statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities.

AGENDA

Highlights	Guillaume Daniellot
Financials	Yang Xu
Recent achievements & strategy	Guillaume Daniellot
Outlook 2024	Guillaume Daniellot
Q&A	Guillaume Daniellot, Yang Xu

straumanngroup



STRONG GROWTH IN THE FIRST HALF-YEAR AND SECOND QUARTER

RESULTS AND OUTLOOK BASED ON CONTINUING OPERATIONS (EXCLUDING DRSMILE)




straumanngroup

¹ Organic growth excluding FX and M&A effects ²2023 full year average FX ³ Barring unforeseen events

VARIED REGIONAL GROWTH DYNAMICS REMAIN


ORGANIC REVENUE GROWTH IN THE SECOND QUARTER





STRONG SECOND QUARTER REVENUE GROWTH


REVENUE DEVELOPMENT BREAKDOWN (IN CHF MILLION, ROUNDED) - CONTINUING OPERATIONS



8 ¹ including discontinued operations related to DrSmile business, EMEA organic revenue growth was 4.1%, and Group was 10.9%


SOLID CORE GROSS MARGIN AT 72.5%





9

CORE EBIT MARGIN AT 27.8%




IN %, ROUNDED



DEVELOPMENT FREE CASH FLOW

IN CHF MILLION, ROUNDED



HALF-YEAR CORE FINANCIALS AT A GLANCE

BUSINESS PERFORMANCE AND PRODUCTIVITY OFFSET CURRENCY HEADWINDS

In CHF million, rounded	HY1 2024	% of revenue	Margin change	Change in %	Comments
Revenue	1'273			17.6%	
COGS	-350	27.5%		25.8%	
GROSS PROFIT	923	72.5%	-180 bps		FX headwind -100 bps
Operating expenses	-575	45.1%		11.9%	
EBIT	354	27.8%	+70 bps		FX headwind -190 bps
Financial result	-6	0.5%		-70.4%	
Associates	-6	0.5%		26.6%	
Income tax	-60	4.7%		31.9%	
NET PROFIT (from continuing operations)	282	22.2%	+170 bps		FX headwind -170 bps
Loss from discontinued operations	-31				
NET PROFIT	251	19.7%	+100 bps		FX headwind -180 bps
Basic EPS (from continuing operations)	1.76			11.0%	

straumanngroup

GROUP HALF-YEAR RESULTS


CONTINUING OPERATIONS VERSUS INCLUDING DISCONTINUED OPERATIONS (DRSMILE BUSINESS)

	Organic revenue growth	Core EBIT margin	Core EBIT margin (2023 FX ¹⁾)
Continuing operations	+16.1%	27.8%	28.9%
Group incl. disc. ops.	+12.9%	24.9%	26.0%

13 ¹ at 2023 full-year average FX rates

straumanngroup

GOOD MOMENTUM CONTINUED ACROSS ALL B2B BUSINESSES



straumanngroup



INNOVATION AND EDUCATION - KEY PILLARS OF OUR SUCCESS

INTENSIFIED EDUCATION EFFORTS WITH ITI WORLD SYMPOSIA BEING THE HIGHLIGHT - A GREAT SUCCESS



Innovations shown at ITI








iExcel

PROGRESS WITH OUR STRAUMANN AXS DIGITAL PLATFORM

DIGITAL TRANSFORMATION: CREATING AN INTEGRATED CUSTOMER EXPERIENCE WITH AI-DRIVEN APPLICATIONS



straumanngroup

17


NEW PROSTHETICS SOLUTION UN!Q LAUNCHED IN NAM

CLOUD BASED ON-DEMAND SERVICE WITH TRULY CUSTOMER-CENTRIC APPROACH



straumanngroup

IEXCEL LAUNCH IN NAM – POSITIVE CUSTOMER FEEDBACK



"A unified prosthetic platform with a single abutment connection is a game changer. It makes implant dentistry safer and more efficient."


Dr. German Gallucci, Boston, MA

straumann group

19

CLEARCORRECT TO ACCELERATE COMMERCIALIZATION INVESTMENT FOCUS TO BE INCREASED


Technology Service Go-to-market



straumanngroup

DRSMILE TO BE SOLD TO IMPRESS GROUP

ENHANCED PATIENT EXPERIENCE AND LARGER GEOGRAPHICAL FOOTPRINT



21 The transaction is expected to close in due course

straumanngroup

PAVING THE PATH FORWARD: LEADERSHIP TRANSITIONS

Sara Dalmasso joining Straumann Head of DSO



Arnoud Middel Chief People Officer Following Alastair Robertson



Thomas Friese new member EMB Chief Technology & Information Officer Former Chief Technology Officer



Matthias Schupp leaving Straumann Group CEO of Medartis Former Head of LATAM



straumanngroup

OUTLOOK 2024

UPDATED OUTLOOK 2024

BARRING UNFORESEEN CIRCUMSTANCES

Market environment and assumption

- Uncertain economic environment remains
- Group believes global patient flow should remain stable
- Outgrowing market vs. prior year

Revenue and profitability

- Organic revenue growth in the low double-digit percentage range
- Profitability in the 27-28% range at constant 2023 currency rates¹

Growth ambition 2030 confirmed

24 Continuous operations; at 2023 full year average exchange rates




CALENDAR OF UPCOMING INVESTOR EVENTS


2024	Event	Location
15-16 Aug	Jefferies Roadshow	London
4-5 Sep	Goldman Sachs European Med-tech Conference	London
10-11 Sep	Kepler Cheuvreux Autumn Conference	Paris
18-19 Sep	Bank of America Global Healthcare Conference	London
29 Oct	Straumann Q3 results	

straumanngroup

26

CURRENCY EXPOSURE





Average exchange rates (rounded)		Closing	FX sensitivity (+/- 10%) on FY				
		2022	2023	Jun 2024	Jun 2024	Revenue	EBIT
1	EURCHF	1.004	0.973	0.959	0.962	+/- 31m	+/- 10m
1	USDCHF	0.950	0.899	0.887	0.899	+/- 33m	+/- 17m
1	BRLCHF	0.184	0.180	0.175	0.163	+/- 8m	+/-1m
1	CNYCHF	0.141	0.127	0.123	0.124	+/- 19m	+/- 15m

straumanngroup

REPORTED FINANCIALS AT A GLANCE

In CHF million, rounded	HY1 2024	% of revenue	Margin change	Change in %	Comments
Revenue	1'273			17.6%	
COGS	-355	27.9%		25.8%	
GROSS PROFIT	918	72.1%	-210 bps		FX headwind -100 bps
Operating expenses	-589	46.2%		10.6%	
EBIT	336	26.4%	+100 bps		FX headwind -190 bps
Financial result	-5	0.4%		-80.6%	
Associates	-6	0.5%		26.6%	
Income tax	-56	4.4%		17.8%	
NET PROFIT (from continuing operations)	268	21.1%	+320 bps		FX headwind -180 bps
Loss from discontinued operations	-37				
NET PROFIT	232	18.2 %	+200 bps		FX headwind -190 bps
Basic EPS (from continuing operations)	1.67			18.5%	

straumanngroup

CORE RESULTS RECONCILIATION

(in CHF 1 000)	IFRS	M&A	Restructuring	Legal cases	CORE
Revenue	1 273 232			,	1 273 232
Cost of goods sold	(354 833)	2 877	1 492		(350 464)
Gross profit	918 399	2 877	1 492		922 768
Other income	6 379				6 379
Distribution expense	(241 273)	3 199	76		(237 997)
Administrative expense	(347 446)	5 1 2 9	580	5 000	(336 738)
Operating profit	336 059	11 204	2 148	5 000	354 412
Finance income	88 604	(10 284)			78 320
Finance expense	(94 102)	9 297			(84 805)
Share of result of associates	(5 858)				(5 858)
Profit before income tax	324 703	10 218	2 148	5 000	342 069
Income tax expense	(56 467)	(2 533)	(446)	(552)	(59 997)
NET PROFIT FROM CONTINUING OPERATIONS	268 236	7 685	1 703	4 448	282 072
Loss from discontinued operations, net of tax	(36 521)	289	5 564		(30 669)
NET PROFIT	231 715	7 974	7 266	4 448	251 403
Attributable to:					
Shareholders of the parent company	230 372	7 927	7 266	4 448	250 013
Non-controlling interests	1 343	47			1 389
Earnings per share (EPS):					
Earnings per share for the period attributable to the owners of the parent:					
Basic (in CHF)	1.45				1.57
Diluted (in CHF)	1.44				1.57
Thereof continuing operations:					
Basic (in CHF)	1.67				1.76
Diluted (in CHF)	1.67				1.76
Operating profit	336 059	11 204	2 148	5 000	354 412
Depreciation & amortization	70 391	(8 391)	(466)		61 534
EBITDA	406 450	2 814	1 682	5 000	415 946

straumanngroup

